Gastrointestinal Stromal Tumor (GIST)

Many GISTs are asymptomatic in their early stages and are often discovered incidentally during imaging for other issues. When symptoms do occur, they typically relate to the tumor's size or its impact on digestive function. Patients may experience persistent abdominal pain or discomfort, a feeling of fullness after eating only a small amount, or nausea and vomiting. Because GISTs can bleed internally, signs of anemia—such as fatigue and weakness—or the presence of blood in the stool are also significant clinical indicators that require professional investigation.

GISTs are not typically linked to lifestyle choices like diet or smoking. Instead, the development of these tumors is predominantly driven by genetic mutations. While the majority of GIST cases are sporadic (occurring by chance), a very small percentage are associated with rare hereditary conditions, such as Neurofibromatosis type 1 or familial GIST syndromes. As with many oncological conditions, the risk of developing a GIST increases with age, with most diagnoses occurring in individuals over 50 years of age.

Diagnosing a GIST involves a combination of high-resolution imaging and pathological analysis. Endoscopy and endoscopic ultrasound (EUS) are essential for visualizing the tumor within the gut wall and allowing for a fine-needle aspiration biopsy. CT or MRI scans are then used to map the tumor’s exact location, size, and relationship to nearby organs. Crucially, tissue samples undergo immunohistochemistry testing to identify specific proteins (like CD117 or DOG1), which confirms the diagnosis and helps tailor the treatment plan, including the potential use of targeted molecular therapies alongside surgical resection.